Biolase (BIOL) Misses Q2 EPS by 3c

Biolase (NASDAQ: BIOL) reported Q2 EPS of ($0.06), $0.03 worse than the analyst estimate of ($0.03). Revenue for the quarter came in at $12.6 million versus the consensus estimate of $14.15 million.

For earnings history and earnings-related data on Biolase (BIOL) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• Prenetics Global (PRE) Tops Q2 EPS by 18c
• uCloudlink Group Inc. (UCL) Misses Q2 EPS by 1c ; Offers Guidance